Objective:

To inform about the FDA approval of the XFG-adapted COVID-19 vaccine for specific populations.

Approach:

• Approval Details: The FDA approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for adults aged 65 and older and patients aged 5 to 64 with at least one underlying condition.
• Vaccine Composition: The approval was for the 2026 to 2027 formulation targeting the XFG variant, based on FDA guidance.
• Data Supporting Approval: Approval was based on clinical, nonclinical, and real-world data demonstrating safety and effectiveness.
• Immune Response: The XFG-adapted vaccine generated immune responses against several circulating SARS-CoV-2 variants.
• Distribution: Shipping of the updated vaccine will begin immediately, with availability expected soon.

Key Findings:

• Over 5 billion doses of COMIRNATY have been distributed globally.
• The vaccine should not be administered to individuals with a history of severe allergic reactions to previous doses.
• Myocarditis and pericarditis have been reported, particularly in males aged 12 to 24 years.
• Common adverse events include injection-site reactions, fatigue, headache, and gastrointestinal symptoms.
• Immunocompromised patients may have a reduced immune response to the vaccine.

Interpretation:

Vaccination may not protect all recipients, and there is a remote chance of severe allergic reactions.

Limitations:

• Patients with a history of severe allergic reactions to the vaccine or its components should not receive it.
• Immunocompromised individuals may not achieve adequate immune responses.

Conclusion:

The XFG-adapted vaccine is now approved for high-risk populations, with immediate distribution planned.

Sources:

• BioNTech